RE:RE:RE:RE:Now What?plantrader wrote: Of course we don't know if any bigger companies are interested in Theralase at all right now. And I assume it's possible that there might be firms looking at Theralase and saying: Ehhh, they aren't at risk of getting anything to market any time soon so let's just watch and see if they run out of money.
Meaning, the risk of doing nothing seems to be low from a 3rd party standpoint, doesn't it? The stock is lackadaisical, most of the company's work is preclinical and their sole PII trial is lacking the needed data for BTD (per the May 30th report) at this point. Let alone final FDA approval which also isn't near-term right now. And no mention of AA as a goal in quite some time now.
If they can get BTD and lock in substantial funding, maybe they will start to be taken more seriously.
Imo, the added validation that a BTD would provide should be the clincher that finally gets Pharma more seriously interested. At that point, any "Ehhh" becomes an "Oh sh$t", if I continue to be ignorant or stay on the sidelines, my competitor can dive in for the kill & have the potential to corner a significant part of a many-billions dollar market! IMO..